Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial.

CONCLUSIONS: There is no evidence to support efficacy of bosentan as an antifibrotic treatment for patients with steroid-resistant pulmonary sarcoidosis. Bosentan was well tolerated and no drug-related adverse effects were observed within the study population. TRIAL REGISTRATION: ISRCTN registry, ISRCTN73579020. PMID: 30378090 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30378090?dopt=Abstract

Source: Swiss Medical Weekly - October 22, 2018 Category: General Medicine Authors: Hostettler K, Baty F, Kleiner R, Junker L, Tamm M, Brutsche M Tags: Swiss Med Wkly Source Type: research